Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype
In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a...
5-Apr-2024 3:50 PM EDT
Add to Favorites